4-carbamoyl-4-{[6-(difluoro-phosphono-methyl)-naphthalene-2-carbonyl]-amino}-butyric acid

A synthetic small molecule belonging to the class of glutamic acid derivatives, with the molecular formula C17H17F2N2O7P and a molecular weight of approximately 430.3 g/mol. It is primarily known as an experimental compound and has not been approved for clinical use in any country. The compound is notable for its activity as an inhibitor of protein tyrosine phosphatase 1B (PTPN1), a target implicated in metabolic disorders such as diabetes and obesity, as well as certain cancers. Its mechanism involves binding to the catalytic domain of PTPN1, thereby inhibiting its phosphatase activity[8][10]. The drug has been studied structurally in complex with human PTP1B but does not have reported clinical trials or approved indications[2][8].

Other names

(4S)-4-carbamoyl-4-({6-[difluoro(phosphono)methyl]naphthalen-2-yl}formamido)butanoic acidN~2~-{6-[Difluoro(phosphono)methyl]-2-naphthoyl}-L-alpha-glutamine